CytRx Corp. Company Profile (NASDAQ:CYTR)

Analyst Ratings

Consensus Ratings for CytRx Corp. (NASDAQ:CYTR) (?)
Ratings Breakdown: 1 Hold Rating(s), 4 Buy Rating(s)
Consensus Rating:Buy (Score: 2.80)
Consensus Price Target: $6.08 (918.13% upside)

Analysts' Ratings History for CytRx Corp. (NASDAQ:CYTR)
Show:
DateFirmActionRatingPrice TargetActions
7/15/2016Jefferies GroupReiterated RatingHold$2.50 -> $0.75View Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/12/2016S&P Equity ResearchLower Price Target$1.04 -> $0.75View Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/12/2016FBR & CoLower Price TargetOutperform$8.00 -> $3.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/23/2016HC WainwrightReiterated RatingBuy$10.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/28/2016AegisBoost Price TargetBuy$9.00 -> $12.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/6/2015Oppenheimer Holdings Inc.Reiterated RatingOutperform$10.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/26/2014 forward)

Earnings

Earnings History for CytRx Corp. (NASDAQ:CYTR)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/1/2016        
5/11/2016Q116($0.26)($0.19)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/3/2015Q315($0.24)($0.11)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/3/2015Q215($0.27)($0.21)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/1/2015Q115($0.21)$0.31ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/10/2015($0.27)($0.24)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/4/2014Q314($0.25)($0.10)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/6/2014Q214($0.20)($0.28)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/1/2014Q413($0.18)$0.09ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/5/2014($0.17)($0.25)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
10/29/2013Q313($0.22)($0.33)$0.20 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/6/2013Q2 2013($0.19)($0.11)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/9/2013Q113($0.15)($0.23)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/11/2013Q4 2012($0.20)($0.21)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/9/2012Q312$0.07ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for CytRx Corp. (NASDAQ:CYTR)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20162($0.21)($0.21)($0.21)
Q2 20163($0.22)($0.17)($0.19)
Q3 20163($0.22)($0.12)($0.18)
Q4 20163($0.36)($0.12)($0.23)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for CytRx Corp. (NASDAQ:CYTR)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for CytRx Corp. (NASDAQ:CYTR)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
12/3/2013Scott Bradford Pattersonmajor shareholderBuy284,979$2.44$695,348.76View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/7/2013Scott Bradford PattersonMajor ShareholderBuy50,000$2.06$103,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/1/2013Scott Bradford PattersonMajor ShareholderBuy4,083$2.70$11,024.10View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/20/2013Scott Bradford PattersonMajor ShareholderBuy3,980$2.61$10,387.80View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/13/2013Scott Bradford PattersonMajor ShareholderBuy55,360$2.67$147,811.20View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/22/2012Scott Bradford PattersonMajor ShareholderBuy180,000$2.51$451,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/18/2012Scott Bradford PattersonMajor ShareholderBuy1,200,000$2.50$3,000,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for CytRx Corp. (NASDAQ:CYTR)
DateHeadline
07/26/16 09:37 PMIMPORTANT NOTICE TO SHAREHOLDERS: Brower Piven Notifies Shareholders of Securities Class Action Lawsuit …
07/26/16 07:10 PMIMPORTANT NOTICE TO SHAREHOLDERS: Brower Piven Notifies Shareholders of Securities Class Action Lawsuit And Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In CytRx Corporation To Contact Brower Piven Before The L - [GlobeNewswire] - STEVENSON, Md., July 26, 2016-- The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court ...
07/26/16 04:36 PMIMPORTANT SHAREHOLDER NOTICE: Khang & Khang LLP Announces the Filing of a Securities Class Action Lawsuit Against CytRx Corporation and Reminds Investors With Losses to Contact the Firm - [Business Wire] - Khang & Khang LLP announces that a class action lawsuit was filed against CytRx Corporation . Investors who purchased or otherwise acquired shares between November 18, 2014 and July 11, 2016 inclusive , are encouraged to contact the Firm prior to the September 23, 2016 lead plaintiff motion deadline.
07/26/16 03:18 PMSHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of CytRx Corporation of Commencement of a Class Action Lawsuit and a Lead Plaintiff Deadline of September 23, 2016 – CYTR - [GlobeNewswire] - NEW YORK, July 26, 2016-- The following statement is being issued by Levi & Korsinsky, LLP:. To: All persons or entities who purchased or otherwise acquired securities of CytRx Corporation between November ...
07/26/16 11:48 AMCytRx Hit With Investor Suit Related To FDA Hold On Drug
07/25/16 08:20 PMIMPORTANT INVESTOR NOTICE: Lundin Law PC Announces an Investigation of CytRx Corporation and Advises ... - Business Wire (press release)
07/25/16 02:48 PMGlancy Prongay & Murray Announces the Filing of a Securities Class Action on Behalf of CytRx Corporation …
07/25/16 01:45 PMIMPORTANT INVESTOR NOTICE: Lundin Law PC Announces an Investigation of CytRx Corporation and Advises Investors with Losses to Contact the Firm - [Business Wire] - Lundin Law PC announces it is investigating claims against CytRx Corporation concerning possible violations of federal securities laws.
07/25/16 12:47 PMGlancy Prongay & Murray Announces the Filing of a Securities Class Action on Behalf of CytRx Corporation Investors and Encourages Investors to Contact the Firm - [Business Wire] - Glancy Prongay & Murray LLP announces that it has filed a class action lawsuit in the United States District Court for the Central District of California on behalf of investors who purchased CytRx Corporation securities between November 18, 2014, and July 11, 2016, inclusive .
07/25/16 08:14 AMCytRx Corporation (CYTR) Shares are Down -4.38% – Trade Calls - Trade Calls
07/21/16 03:41 PMInvestigation of CytRx Corporation Announced by Law Offices of Howard G. Smith
07/20/16 10:51 PMSHAREHOLDER ALERT: Goldberg Law PC Announces An...
07/20/16 04:42 PMGlancy Prongay & Murray Commences Investigation on Behalf of CytRx Corporation Investors - Business Wire (press release)
07/20/16 04:42 PMCytRx Corporation (CYTR) Drops 5.51% on July 18 - Equities.com
07/20/16 11:19 AMSHAREHOLDER ALERT: Goldberg Law PC Announces An Investigation of Claims Against CytRx Corporation and Advises Investors With Losses To Contact The Firm - [Business Wire] - Goldberg Law PC announces that it is investigating CytRx Corporation concerning possible violations of federal securities laws.
07/20/16 09:30 AMGlancy Prongay & Murray Commences Investigation on Behalf of CytRx Corporation Investors - [Business Wire] - Glancy Prongay & Murray LLP announces an investigation on behalf of investors of CytRx Corporation concerning the Company and its officers’ possible violations of federal securities laws.
07/20/16 07:54 AMCytRx (CYTR) Is in Oversold Territory: What's Next? -
07/19/16 09:39 AMInvestigation for Investors over Possible Violations of Securities Laws by CytRx Corporation (NASDAQ:CYTR)
07/19/16 08:23 AMMerck KGaA's Multiple Sclerosis Drug under Review in EU -
07/18/16 04:15 PMSHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Possible Violations of Federal Securities Laws by Certain Officers and Directors of CytRx Corporation - [Business Wire] - Levi & Korsinsky announces it has commenced an investigation of CytRx Corporation concerning possible violations of federal securities laws by the Company and/or certain of its officers and directors.
07/18/16 03:39 PMIntraday Active Biotech Stocks News: Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS), CytRx Corporation (NASDAQ ... - The Voice Registrar
07/18/16 07:36 AMAdeptus Health (ADPT) Q2 Earnings: Will it Beat Estimates? -
07/16/16 04:27 AMForm SC 13G CYTRX CORP Filed by: SABBY MANAGEMENT, LLC - StreetInsider.com
07/16/16 04:27 AMStock Update (NASDAQ:CYTR): CytRx Corporation Announces Pricing of $20 Million Public Offering of Common Stock ... - Smarter Analyst
07/16/16 04:27 AMCytRx Corporation (CYTR) Drops 8.27% on July 14 - Equities.com
07/16/16 04:27 AMBRIEF-Cytrx Corp announces pricing of $20 mln public offering - Reuters
07/15/16 03:54 PMCYTRX CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events -
07/15/16 02:33 PMHere's How CytRx Corporation (CYTR) Plans to Recover from Damage
07/15/16 07:52 AMSHAREHOLDER NOTICE: Khang & Khang LLP Announces an Investigation of CytRx Corporation and Reminds ... - Business Wire (press release)
07/15/16 07:52 AMCytRx Corporation (NASDAQ:CYTR) & NXP Semiconductors NV (NASDAQ:NXPI) Stocks in Focus - Money News (press release)
07/15/16 07:52 AM3 Stocks to Watch on Friday: CytRx Corporation (CYTR), Juno Therapeutics Inc (JUNO) and Line Corp (ADR) (LN) - Investorplace.com
07/15/16 06:58 AMCytRx Corporation Announces Pricing of $20 Million Public Offering of Common Stock and Warrants - [at noodls] - LOS ANGELES, July 15, 2016 /PRNewswire/ -- CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that it has priced a registered ...
07/14/16 04:43 PMSHAREHOLDER NOTICE: Khang & Khang LLP Announces an Investigation of CytRx Corporation and Reminds Investors with Losses to Contact the Firm - [Business Wire] - Khang & Khang LLP announces that it is investigating claims against CytRx Corporation concerning possible violations of federal securities laws.
07/14/16 04:38 PMCytRx Corporation Announces Proposed Public Offering of Common Stock and Warrants - [at noodls] - LOS ANGELES, July 14, 2016 /PRNewswire/ -- CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology today announced a proposed registered public offering ...
07/14/16 04:14 PM5:14 pm CytRx announces proposed registered public offering of its common stock and one year warrants to purchase common stock; size not disclosed -
07/14/16 03:47 PMINVESTOR ALERT: Investigation of CytRx Corporation Announced by Law Offices of Howard G. Smith
07/14/16 01:29 PMCYTRX CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Material Modification to Rights of Securit -
07/14/16 06:17 AMCytRx Corporation (CYTR) Hits New 52-week Low During July 12 Session - Equities.com
07/14/16 06:17 AMCytRx Corporation (CYTR) Drops 59.76% on July 12 - Equities.com
07/13/16 03:37 PMSHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of CytRx Corporation (CYTR) - PR Newswire (press release)
07/13/16 03:37 PMSHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of CytRx Corporation (CYTR) - PR Newswire (press release)
07/13/16 03:37 PMCytRx Corporation (NASDAQ:CYTR) & State Street Corp (NYSE:STT) Stocks Trending Alert - Money News (press release)
07/13/16 03:37 PMCytRx Corporation (NASDAQ:CYTR) & State Street Corp (NYSE:STT) Stocks Trending Alert - Money News (press release)
07/13/16 01:21 PMWhat’s Next For CytRx Corporation (CYTR) Holders? -
07/13/16 09:37 AMCytRx (CYTR) Stock Takes The Plunge | Here’s Why
07/13/16 09:37 AMCytRx reports initial results from phase 3 study of aldoxorubicin in patients with second-line soft tissue sarcoma
07/13/16 09:37 AMCytRx Corporation (NASDAQ:CYTR) Price Target Reduced by 63% to $3: FBR Capital Markets
07/13/16 09:37 AMFBR Slashes Price Target on CytRx Corporation (CYTR) Following Clinical Trial Setback
07/13/16 09:37 AMCytRx Corp. (CYTX) Sank To A New Low After Phase 3 Results Disappoint
07/13/16 09:37 AMCytRx Disappoints on Latest Cancer Trial Data, Shares Nosedive

Social

About CytRx Corp.

CytRx Corp. logoCytRx Corporation is a biopharmaceutical research and development company specializing in oncology. The Company is focused on the clinical development of aldoxorubicin, its modified version of the chemotherapeutic agent, doxorubicin. It is engaged in Phase III trials for aldoxorubicin as a therapy for patients with soft tissue sarcoma (STS) whose tumors have progressed after treatment with chemotherapy. It is also involved in evaluating aldoxorubicin in a Phase IIb clinical trial in small cell lung cancer; a Phase II clinical trial in human immunodeficiency virus-related Kaposi's sarcoma; a Phase II clinical trial in patients with late-stage glioblastoma (brain cancer); a Phase Ib trial in combination with ifosfamide in patients with STS, and a Phase Ib trial in combination with gemcitabine in subjects with metastatic solid tumors. It is engaged in the pre-clinical development for DK049, an anti-cancer drug conjugate that utilizes its Linker Activated Drug Release (LADR) technology.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: CYTR
  • CUSIP:
Key Metrics:
  • Previous Close: $0.60
  • 50 Day Moving Average: $1.8126
  • 200 Day Moving Average: $2.3786
  • P/E Ratio: N/A
  • P/E Growth: 0.0000
  • Market Cap: $39.89M
  • Beta: 1.66
  • Current Year EPS Consensus Estimate: $-0.7100 EPS
  • Next Year EPS Consensus Estimate: $-0.2800 EPS
Additional Links:
CytRx Corp. (NASDAQ:CYTR) Chart for Tuesday, July, 26, 2016